Table 2. Treatments for the residual and non-residual groups after vacuum-assisted breast biopsy.
| Variable | No. (%) | χ2 | P | |
|---|---|---|---|---|
| Residual group | Non-residual group | |||
| Time to surgery after VABB | 1.841 | 0.072 | ||
| Mean ± SD (days) | 31.45±11.61 | 26.56±11.50 | ||
| Surgery type | 0.132 | 0.717 | ||
| BCS | 25 (40.3%) | 12 (44.4%) | ||
| Mastectomy | 37 (59.7%) | 15 (55.6%) | ||
| Axillary staging methods | 3.828 | 0.147 | ||
| SLNB | 26 (41.9%) | 9 (33.3%) | ||
| ALND | 36 (58.1%) | 18 (66.7%) | ||
| Hormone therapy | 3.013 | 0.083 | ||
| Yes | 58 (93.5%) | 22 (81.5%) | ||
| No | 4 (6.5%) | 5 (18.5%) | ||
| Chemotherapy | 3.174 | 0.075 | ||
| Yes | 26 (41.9%) | 6 (22.2%) | ||
| No | 36 (58.1%) | 21 (77.8%) | ||
| Radiotherapy | ||||
| Yes | 25 (40.3%) | 8 (29.6%) | 0.922 | 0.337 |
| No | 37 (59.7%) | 19 (70.4%) | ||
| Targeted therapy | ||||
| Yes | 7 (11.3%) | 1 (3.7%) | 1.323 | 0.250 |
| No | 55 (88.7%) | 26 (96.3%) | ||
| Size of residual tumors | 4.466 | 0.000 | ||
| Mean ± SD (cm) | 0.69±0.81 | 0±0 | ||
| Tumor staging | 19.637 | 0.001 | ||
| Tis | 4 (6.5%) | 0 (0.0%) | ||
| T1a | 0 (0.0%) | 0 (0.0%) | ||
| T1b | 2 (3.2%) | 7 (25.9%) | ||
| T1c | 38 (61.3%) | 20 (74.1%) | ||
| T2 | 17 (27.4%) | 0 (0.0%) | ||
| T3 | 1 (1.6%) | 0 (0.0%) | ||
| TNM staging | 16.879 | 0.054 | ||
| 0 | 7 (11.3%) | 0 (0.0%) | ||
| I | 35 (56.5%) | 27 (100.0%) | ||
| II | 12 (19.4%) | 0 (0.0%) | ||
| III | 8 (12.9%) | 0 (0.0%) | ||
BCS, breast-conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; Tis, carcinoma in situ; T1a, tumor size of 0.1–0.5 cm; T1b, tumor size of 0.5–1 cm; T1c, tumor size of 1–20 mm; T2, tumor size of 20–50 mm; T3, tumor size of >50 mm.